Skip to main content

Advertisement

Table 1 (abstract P070). See text for description

From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)

  FMF + Definite JSPA FMF + Probable JSPA FMF patients without JIA and JSpA FMF + JIA (except ERA or JSpA)
Patients, n 32 5 268 15
Female, n (%) 10 (31.25%) 1 (20%) 148 (55.22%) 10 (66.66%)
Age of disease onset, mean ±SD  years 7.19 ± 3.68 5.60 ± 4.93 4.91 ± 3.40 4.93 ± 3.32
Age at study, mean ±SD years 14.84 ± 3.70 13.40 ± 1.67 12.51 ± 4.43 10.73 ± 3.57
M694V mutation n(%) 19 / 30 (63.33%) 3 (60%) 148 / 245 (60.40%) 11 (73.33%)
Disease onset >6 yrs 26 (81.25%) 5 (100%)   6 (40%)
Oligorthritis 21 (65.62%) 1 (20%) 14 (93.33%)
Inflammatory back pain 17 / 32 (53.1%) 3 / 5(60%) 0 (0%)
Enthesopathy   3 / 5(60%) 0 (0%)
Sacroiliitis 22 /32(68.7%) 0 / 1 (0%) 0 /5 (0%)
Coxofemoral Arthritis 14 /21(66.7%) 19/32(59.37%) 2 / 5(40%) 0 / 15 (0%)
Tarsometatarsal sensivity   1 / 5(20%) 1 / 7(14.3%)
HLA-B 27 Positivity 12 / 32 (37.5%) 0 / 1(0%) 0 / 3(0%)
Male Gender   4 / 5(80%) 5 /15(33.3%)
Response to NSAID 9 / 22(40.9%) 4 / 5(80%) 2 / 7(28.6%)
Limitation in Schober test (< 4 cm) 22 /32(68.7%) 2 / 5(40%) 0 / 7(0)
21 / 26(80.7%)
Family history of SpA group of disease, dactylitis, psoriasis or presence of IBD 7 / 32(21.87%) 1 / 5(20%) 1 /8(12.5%)
10 / 32(31.3%)